Sequence: Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr(Cys1&Cys6,Cys2&Cys10, Cys5&Cys13 bridge)
CAS NO.: 851199-59-2
Molecular Formula: C59H79N15O21S6
Molecular Weight: 1526.74
Appearance: White powder
Application: Pharma grade or research purpose
The intestinal and intestinal secretion-promoting effects of this drug and the improvement of colonic hyperalgesia are thought to contribute to the improvement of bowel movement abnormalities and abdominal pain, abdominal discomfort in constipation-type irritable bowel syndrome.
Linaclotide is an orally administered, peptide agonist of guanylate cyclase 2C for the treatment of irritable bowel syndrome. Chemically, it is a heterodetic cyclic peptide and consists of fourteen amino acids. This compound reduces activation of colonic sensory neurons, reducing pain; and activates colonic motor neurons, which increases smooth muscle contraction and thus promotes bowel movements.
It was approved by the FDA in August 2012 for the treatment of chronic idiopathic constipation and constipation predominant irritable bowel syndrome (IBS-C) in adults.Linaclotide is the only FDA-approved GC-C (guanylate cyclase-C) agonist that acts locally in the gut. Ironwood Pharmaceuticals says this is the first new prescription option for adults with these disorders in over six years.
Linaclotide is a 14-amino acid peptide that is a uridine cyclase C receptor agonist in intestinal epithelial cells. Experiments have shown that the drug promotes fluid secretion and transport.
Linaclotide is used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause.
Aluminum Foil Bag, Drum, Vacuum Packed
Hello, please leave your name and email here before chat online so that we won't miss your message and contact you smoothly.